Kimberly-Clark Corporation KMB
Composite 49/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 18/100 — a strong mark against it.
Income ranks 83/100 — a strong point in its favour. Quality ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 51/100 — a slight point in its favour.
Growth ranks 18/100 — a strong mark against it. Valuation ranks 36/100 — a moderate mark against it. Momentum ranks 47/100 — a slight mark against it.
What the company does Kimberly-Clark (KMB) makes branded personal and household care products—diapers, tissues, wipes, feminine care, and incontinence items—sold globally under Huggies, Kleenex, Kotex, Scott, and Depend. Roughly 60% of revenue comes from North America, with the rest from international markets.
Key financials KMB posts high returns: ROE 105%, ROA 10%, ROCE 21% and strong margins (gross 38%, operating 19%, net 12%). Revenue grew 1% while EPS fell 32% year-over-year. Profitability metrics like Piotroski F-Score 7/9 and Altman Z 3.35 indicate solid financial health, though debt/equity is elevated at 3.49.
Stock health The stock shows mixed momentum: up 16% over 3 months but down 14% from its 52-week high and 15% off peak. RSI(14) at 53 suggests neutral technical positioning. Dividend yield is 4.6% with a 69% payout ratio, supported by strong income score 83.
Price vs fair value KMB trades at a discount of 7.40% to the analyst mean target of 118.60. - Recent China diaper disruption clouds 2026 outlook (Zacks) - Tariff refund of $45M in 2025 provides partial relief (Supply Chain Dive) - Transformation momentum cited as 3-month rally gains steam (Zacks) - Analyst debate persists over whether low valuation offsets growth risks (Zacks)
Looking forward Forward P/E of 15x and PEG of 0.32 suggest undemanding valuation, but growth score of 28 and China exposure remain headwinds. Management’s Hesperaloe fiber initiative may support long-term sustainability claims (Simply Wall St).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.